AR-V7 as a Biomarker in CRPC

Publication
Article
Special ReportsGenitourinary (Issue 2)
Issue 2

Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine, discusses the potential of AR-V7 as a biomarker in early stage castration-resistant prostate cancer (CRPC).

Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine, discusses the potential of AR-V7 as a biomarker in early stage castration-resistant prostate cancer (CRPC).

<<<

View more from the GU Cancers Special Report

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides
Related Content